| Accession Number: | 0001219036-21-000010 |
| Date: | 2021-06-25 |
| Issuer: | MYRIAD GENETICS INC (MYGN) |
| Original Submission Date: |
LANCHBURY JERRY S
320 WAKARA WAY
SALT LAKE CITY, UT 84108
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2021-06-25 | M | 21,360 | a | $19.47 | 287,282 | direct | ||
| COMMON STOCK | 2021-06-25 | S | 21,360 | d | $32.47 | 265,922 | direct | ||
| COMMON STOCK | 2021-06-25 | M | 28,640 | a | $19.47 | 294,562 | direct | ||
| COMMON STOCK | 2021-06-25 | S | 28,640 | d | $31.97 | 265,922 | direct | ||
| COMMON STOCK | 2021-06-25 | S | 33,372 | d | $31.61 | 232,550 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) | 19.47 | 2021-06-25 | deemed execution date | M | 21,360 (d) | 2021-09-13 | common stock 21,360 | $19.47 | 47,280 | direct | ||
| NON-QUALIFIED STOCK OPTION (RIGHT TO BUY) | 19.47 | 2021-06-25 | deemed execution date | M | 28,640 (d) | 2021-09-13 | common stock 28,640 | $19.47 | 18,640 | direct |
| ID | footnote |
|---|---|
| f1 | the transactions reported on this form 4 were effected pursuant to a rule 10b5-1 trading plan. |
| f2 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $31.30 to $31.99, inclusive. the reporting person undertakes to provide to myriad genetics, inc., any security holder of myriad genetics, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| f3 | the shares subject to this option are fully vested and exercisable. |
